YIH
TRML

Y-Intercept (HK)’s Tourmaline Bio TRML Stock Holding History

Y-Intercept (HK)’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,056
Closed -$353K – 2055
2025
Q2 		$353K Buy
+22,056
New +$357K 0.01% 1316
2023
Q3 		– Sell
-3,206
Closed -$97.5K – 1608
2023
Q2 		$97.5K Buy
+3,206
New +$81.8K 0.01% 1108

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Y-Intercept (HK)'s TRML Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 22,056 shares — an estimated $353K sold.

Y-Intercept (HK) first reported a position in TRML in Q2 2023 and held it in 2 quarters. The position peaked at $353K in Q2 2025. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 22,056 Tourmaline Bio shares in Q3 2025, an estimated $353K.
  • Y-Intercept (HK) first reported a position in Tourmaline Bio in Q2 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s Tourmaline Bio position peaked at $353K in Q2 2025.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.